- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04835779
Biometric and Biological Data for Diagnosis and Therapy of Pain Patients (Bio2Treat)
Biometric and Biological Data for Diagnosis and Therapy of Pain Patients German: Biometrische Und Biologische Daten für Die Diagnose Und Therapie Bei Schmerzpatienten
Study Overview
Status
Conditions
Detailed Description
Bio2Watch: In this clinical project part biometric patient data of 24 SFN patients, 3 cancer patients and 21 subjects (control group) will be collected for a period of one year using a PainWatch. The term PainWatch includes an Apple Watch 5 with iPhone 8 and installed app for pain recording. With the aid of the PainWatch, the personal pain sensation in everyday life is documented and personal data such as the pulse rate and the daily number of steps, as well as environmental data, such as the prevailing air pressure, humidity and temperature are recorded. The aim is to use these data as a basis for initial indications of pain-inducing stimuli or combinations of stimuli.
Bio2Patient: In this clinical project part clinically quantifiable tests are carried out, such as quantitative sensory testing (QST), which examines subjective thermal and mechanical sensory perception and pain thresholds. The goal is to determine a specific pain phenotype. In addition, pain evoked potentials (PREPs) are performed to draw conclusions about the function of thin nerve fibers (pain fibers), including projection to the brain. Supplementary SF-36 pain questionnaires are completed to assess the quality of life.For the pain-evoked potentials (PREPs), a total of 20 additional healthy control subjects are to be included (control group D). Four subjects (2 male, 2 female) from each of the age decades 20-29, 30-39, 40-49, 50-59, 60-69 will be included.
Bio2Cell: In the cell-based project part induced pluripotent stem cells (iPS cells) are produced from blood cells of SFN patients, cancer patients and volunteers. These cells will be differentiated into sensory neurons that are relevant in pain processing, so-called nociceptors. Since these nociceptors are derived from the individual patient, they carry the individual genetic characteristics of the patient. These neurons are then analyzed by multi-electrode arrays (MEA). With this method environmental influences such as temperature and air pressure or drugs on the pathophysiology of the patient's are investigated. The main goal is to simulate the conditions, which lead to pain sensation in the context of Bio2Watch and Bio2Patient.
Bio2Integrate: The results from Bio2Watch, Bio2Patient and Bio2Cell will then flow into the software to be developed during the project. Thus, in addition to the identification of stimuli that stimulate pain as well as a genetic correlation to certain markers will be possible. In addition, the targeted modification of the cellular properties of the patient's own sensory neurons through the application of the chemotherapeutic agent can be investigated. To this end, measurements will be made on the cells before and after the application of the substance and compare them with each other. This is the basis for components of the "machine learning " of the Bio2Integrate software.The results of the clinical subprojects are thus an essential component of Bio2Integrate.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Roman Rolke, Prof. Dr.
- Phone Number: +49 241 8080880
- Email: rrolke@ukaachen.de
Study Contact Backup
- Name: Lampert Angelika, Prof. Dr.
- Phone Number: +49 241 80 88811
- Email: alampert@ukaachen.de
Study Locations
-
-
Nordrhein-Westfalen
-
Aachen, Nordrhein-Westfalen, Germany, 52074
- Recruiting
- Uniklinik RWTH Aachen, Klinik für Palliativmedizin
-
Contact:
- Roman Rolke, Prof.Dr.med
- Phone Number: +49-241-8080880
- Email: rrolke@ukaachen.de
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
SFN Patients (Group A): Patients diagnosed with Small Fibre Neuropathia Healthy Volunteers (Group B): Healthy grown-up Volunteers Patients undergoing chemotherapy (Group C): Patients with imminent initiation of neurotoxic chemotherapy in cancer with solid tumors (preferably of the gastrointestinal tract) with the side-effect of SFN development. There are no plans for follow-up recruitment in case no neuropathy develops after chemo.
Healthy Volunteers PREPs (Group D): Healthy grown-up Volunteers. Four subjects (2 male, 2 female) from each of the age decades 20-29, 30-39, 40-49, 50-59, 60-69.
Description
Inclusion Criteria:
Group A: Criteria 1-5 Group B: Criteria 2-5 Group C: Criteria 2-6 Group D: Criteria 2-4
- Small fiber neuropathy (after clinical examination or QST or skin biopsy findings)
- Legal age
- Written declaration of consent
- Persons who are legally competent and mentally capable of following the instructions of the staff
- Sufficient affinity for independent handling of the technology used (PainWatch incl. the corresponding apps) for daily digital pain recording
- Imminent initiation of neurotoxic chemotherapy in cancer with solid tumors (preferably of the gastrointestinal tract) There are no plans for follow-up recruitment in case no neuropathy develops after chemo.
Exclusion Criteria:
For all Groups:
- Persons who are accommodated in an institution by order of the authorities or courts
- Persons who are in a dependent or employment relationship with the auditor
- For test persons: Exclusion, if they carry a known pain-relevant genetic variant/mutation or suffer from a chronic pain disorder analogous to migraine or chronic back pain.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
SFN Patients
Patients with diagnosed Small Fibre Neuropathy
|
Patients undergoing chemotherapy
Patients undergoing chemotherapy and are expected to develop SFN as a result
|
Healthy Volunteer
Healthy test person
|
Healthy Volunteer PREPs
For the pain-evoked potentials (PREPs), 20 additional healthy control subjects are to be included.
Four subjects (2 male, 2 female) from each of the age decades 20-29, 30-39, 40-49, 50-59, 60-69.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PainWatch Data
Time Frame: 12 months
|
pulse rate (/min)
|
12 months
|
PainWatch Data
Time Frame: 12 months
|
number of steps
|
12 months
|
PainWatch Data
Time Frame: 12 months
|
pain perception via App (Questionnaire, pain scale 1-10)
|
12 months
|
Weather Data tracked according to GPS Location
Time Frame: 12 months
|
Temperature (°C)
|
12 months
|
Weather Data tracked according to GPS Location
Time Frame: 12 months
|
Air pressure (Pa)
|
12 months
|
Weather Data tracked according to GPS Location
Time Frame: 12 months
|
Humidity (%)
|
12 months
|
Test result QST
Time Frame: 12 months
|
Measurement exclusively above the back of the foot that is clinically more severely affected by the SFN, in a balanced row alternately above the right or left foot; one back of the foot as test site per subject
|
12 months
|
Test result PREP (over the same back of the foot as in QST measurement)
Time Frame: 12 months
|
P1 Latency (ms)
|
12 months
|
Test result PREP (over the same back of the foot as in QST measurement)
Time Frame: 12 months
|
Peak-to-Peak (microV)
|
12 months
|
Test result PREP (over the same back of the foot as in QST measurement)
Time Frame: 12 months
|
Current intensity (mA)
|
12 months
|
Result SF 36 Questionnaire
Time Frame: 12months
|
Result SF 36 Questionnaire (different scales per question)
|
12months
|
Results of the Multi-Electrode Array investigations
Time Frame: 12 months
|
Spontaneous activity
|
12 months
|
Results of the Multi-Electrode Array investigations
Time Frame: 12 months
|
Synchronicity
|
12 months
|
Results of the Multi-Electrode Array investigations
Time Frame: 12 months
|
Field potential properties
|
12 months
|
Results of the Multi-Electrode Array investigations
Time Frame: 12 months
|
Activity inducing stimuli
|
12 months
|
Efficiency of reprogramming and differentiation of iPS cells
Time Frame: 12 months
|
Success of differentiation will be measured by flow cytometry at around d10 of differentiation.
The percentage of p75 (CD271)-expressing cells will be meassured.
The differentiation is defined as successful if more than 30% of cells express p75.
Only those differentiations will be used for MEA-Recordings.
|
12 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Roman Rolke, Prof. Dr., Universitätsklinikum Aachen, AöR
Publications and helpful links
General Publications
- Lacomis D. Small-fiber neuropathy. Muscle Nerve. 2002 Aug;26(2):173-88. doi: 10.1002/mus.10181.
- Devigili G, Tugnoli V, Penza P, Camozzi F, Lombardi R, Melli G, Broglio L, Granieri E, Lauria G. The diagnostic criteria for small fibre neuropathy: from symptoms to neuropathology. Brain. 2008 Jul;131(Pt 7):1912-25. doi: 10.1093/brain/awn093. Epub 2008 Jun 4.
- Rolke R, Rolke S, Hiddemann S, Mucke M, Cuhls H, Radbruch L, Elsner F, Peuckmann-Post V. [Update palliative pain therapy]. Internist (Berl). 2016 Oct;57(10):959-970. doi: 10.1007/s00108-016-0126-7. German.
- Dworkin RH, O'Connor AB, Kent J, Mackey SC, Raja SN, Stacey BR, Levy RM, Backonja M, Baron R, Harke H, Loeser JD, Treede RD, Turk DC, Wells CD. Interventional management of neuropathic pain: NeuPSIG recommendations. Pain. 2013 Nov;154(11):2249-2261. doi: 10.1016/j.pain.2013.06.004. Epub 2013 Jun 6.
- Coluzzi F, Rolke R, Mercadante S. Pain Management in Patients with Multiple Myeloma: An Update. Cancers (Basel). 2019 Dec 17;11(12):2037. doi: 10.3390/cancers11122037.
- Meents JE, Bressan E, Sontag S, Foerster A, Hautvast P, Rosseler C, Hampl M, Schuler H, Goetzke R, Le TKC, Kleggetveit IP, Le Cann K, Kerth C, Rush AM, Rogers M, Kohl Z, Schmelz M, Wagner W, Jorum E, Namer B, Winner B, Zenke M, Lampert A. The role of Nav1.7 in human nociceptors: insights from human induced pluripotent stem cell-derived sensory neurons of erythromelalgia patients. Pain. 2019 Jun;160(6):1327-1341. doi: 10.1097/j.pain.0000000000001511.
- Mucke M, Cuhls H, Radbruch L, Baron R, Maier C, Tolle T, Treede RD, Rolke R. [Quantitative sensory testing]. Schmerz. 2014 Dec;28(6):635-46; quiz 647-8. doi: 10.1007/s00482-014-1485-4. German.
- Lefaucheur JP, Ahdab R, Ayache SS, Lefaucheur-Menard I, Rouie D, Tebbal D, Neves DO, Ciampi de Andrade D. Pain-related evoked potentials: a comparative study between electrical stimulation using a concentric planar electrode and laser stimulation using a CO2 laser. Neurophysiol Clin. 2012 Jun;42(4):199-206. doi: 10.1016/j.neucli.2011.12.003. Epub 2012 Jan 20.
- Hansen N, Obermann M, Uceyler N, Zeller D, Mueller D, Yoon MS, Reiners K, Sommer C, Katsarava Z. [Clinical application of pain-related evoked potentials]. Schmerz. 2012 Feb;26(1):8-15. doi: 10.1007/s00482-011-1117-1. German.
- Jenkinson C, Coulter A, Wright L. Short form 36 (SF36) health survey questionnaire: normative data for adults of working age. BMJ. 1993 May 29;306(6890):1437-40. doi: 10.1136/bmj.306.6890.1437.
- Lee J, Mawla I, Kim J, Loggia ML, Ortiz A, Jung C, Chan ST, Gerber J, Schmithorst VJ, Edwards RR, Wasan AD, Berna C, Kong J, Kaptchuk TJ, Gollub RL, Rosen BR, Napadow V. Machine learning-based prediction of clinical pain using multimodal neuroimaging and autonomic metrics. Pain. 2019 Mar;160(3):550-560. doi: 10.1097/j.pain.0000000000001417.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 18-018 (Hammersmith Medicines Research Ltd)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Small Fiber Neuropathy
-
PNA Center for Neurological ResearchEisai Inc.Unknown
-
Henry Ford Health SystemOctapharma USA, Inc.RecruitingSmall Fiber Neuropathy | Autoimmune Small Fiber Neuropathy | Inflammatory Polyneuropathy | Immune-Mediated NeuropathyUnited States
-
University of AlbertaCapital Health, CanadaTerminated
-
Johns Hopkins UniversityPfizerCompletedIdiopathic Small Fiber NeuropathyUnited States
-
Beth Israel Deaconess Medical CenterPhoenix Neurological Associates, LTDCompletedSmall Fiber Neuropathy | Idiopathic Peripheral NeuropathyUnited States
-
JFK Medical CenterUnknownPeripheral NeuropathyUnited States
-
Aalborg University HospitalUniversity of Aarhus; Aalborg UniversityNot yet recruitingType 1 Diabetes | Neuropathy, Diabetic | Small Nerve Fiber Neuropathy
-
National Taiwan University HospitalUnknownChronic Kidney Disease | Small-Fiber NeuropathyTaiwan
-
Academisch Ziekenhuis MaastrichtCompletedSmall Fiber NeuropathyNetherlands
-
Academisch Ziekenhuis MaastrichtTerminated